Neuroscience Research - Alzheimer's Focus
Antibodies and reagents focussing on Alzheimer's disease research
|
Newmarket Scientific provides products for neuroscience research with a focus on Alzheimer's disease:
Antibodies, Proteins, ELISA kits and Related reagents.
Some products for Alzheimer's disease research are highlighted below and more information on neuroscience research in general, is available on our Neuroscience Twitter feed Tweets by NKTSciNeuro, including highlighted articles/papers and other resources.
|
|
BDNF belongs to the neurotrophin family and regulate the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycaemia may contribute to some pathologies such as depression, epilepsy, Alzheimer’s Disease and Parkinson’s Disease. BDNF promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. BDNF is also a major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS.
Biosensis BDNF Rapid™ ELISA kit BEK-2211: - Now measure BDNF in serum, cell culture supernatants and brain extracts in less than 3 hours. - Quantify BDNF in Human and Rodent samples against a WHO approved BDNF standard - High sensitivities gives you the advantage of using small sample volumes - Our kits contain pre-coated 96 well strip plates – use only what you need - Also available CE marked (BEK-2211-1P-CE/BEK-2211-2P-CE)
Below: Analysis of two human serum samples: Our kit gives reliable results in a wide dilution range (A) and with high confidence (B)
Related products: BDNF, proBDNF and mature BDNF ELISA kits, BDNF antibodies.
Biosensis Rapid ELISA Kits 2 for 1 promotion.
|
|
Cholesterol is an important cell membrane component which in the brain is found mainly in glial cells and neurons and in the myelin sheaths. Cholesterol does not usually cross the blood-brain-barrier and as a result must be synthesised in situ in the brain, transported between the various cells and then eliminated in order to maintain appropriate levels.
Key to maintaining brain cholesterol homeostasis is the CNS-specific cytochrome P450 enzyme Cholesterol 24-hydroxylase (CYP46A1). This cytochrome P450 enzyme which is mostly expressed in the brain (and to a lesser extent in the retina) helps eliminate excess cholesterol by converting it to 24S-hydroxycholesterol (24HC) which is membrane permeable so it can cross the blood-brain-barrier and reach the systemic circulation where it is further degraded to bile acids once in the liver.
Dysregulation of the activity of CYP46A1 induces changes in the cholesterol levels, which may contribute to the development of neurodegenerative diseases such as Alzheimer's and Huntington’s diseases. In Alzheimer’s disease there is significant CYP46A1 expression in astrocytes and around amyloid plaques and increasing evidence suggests that CYP46A1 has a role in the pathogenesis and progression of neurodegenerative disorders, with increasing CYP46A1 levels in the brain being neuroprotective in Huntington’s disease.
NS reagents: Anti-CYP46A1 antibody Applications: WB IHC Reactivity: Hu Ms Rt
NS reagents: Anti-CYP7B1 Antibody (Cytochrome P450 7B1/cholesterol 7 alpha-hydroxylase) Applications: ELISA IHC WB Reactivity: Hu
|
|
The presence of aggregated amyloid-β peptides (Aβ) is one of the hallmarks of Alzheimer's Disease (AD). However, the form(s) of Aβ-peptides that are associated with this pathology remains unclear. In particular, the neurotoxicity of intraneuronal Aβ accumulation is an area of considerable research and controversy principally because antibodies thought to be specific for Aβ have been shown to actually detect intraneuronal amyloid precursor protein (APP) and not Aβ exclusively.
Our Biosensis MOAB-2 antibody (M-1586-100) is a new pan-specific monoclonal antibody to Amyloid beta residues 1-4 and provides unparalleled staining clarity, stronger reactivity and greater sensitivity than any other Abeta monoclonal antibodies previously available for research. Also, unlike other monoclonals such as 6E10 and 4G8, MOAB-2 does not cross react with APP or APP C-terminal fragments.
The Biosensis formulation of MOAB-2 is also the only one endorsed by the original developers.
Related products: Biosensis APP antibodies, Oligomeric Amyloid-beta ELISA Kits, Amylo-Glo - Amyloid beta plaque staining solution
|
